Inclusion Criteria:  18Y≤Age≤75Y Good Organ Function Expected survival time ≥ 3 months Metastatic/recurrent advanced BRAF+ solid tumors that have been diagnosed histologically and have failed standard treatment Previous failure to standard treatment, intolerance to standard treatment, absence of standard treatment, or insuitability for standard treatment at this stage. ECOG score 0-1; Expected survival time of more than 3 months;  Exclusion Criteria:  Previous treatment with BRAF inhibitors or MEK inhibitors Symptomatic brain or meningeal metastases (unless the patient has been on > treatment for 6 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable). Current or former patients with interstitial lung disease; Active clinical severe infection; A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin. Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation therapy (except palliative radiation therapy), may be given during the study period.